Prior studies of matched primary and recurrent BRCA1/2 mutation-associated breast and ovarian cancers have been limited by small numbers (3–8 patients) or focused only on tumors resistant to PARPi, not the entire breadth of frontline therapy and resistance17,27–31. This evidence concerns the gene BRCA1 and ovarian carcinoma.